To the Editor: With great interest, we read the article "Multibacillary Leprosy in a Child" by Wang *et al*.\[[@ref1]\] The authors have nicely shown the rare presentation in highly unsuspected clinical dermatological case. Authors also have emphasized the importance of early biopsy including Fite-Faraco stain to make a diagnosis of multibacillary leprosy that is important in patients with only atypical cutaneous manifestations. In the case that discussed, the clinical finding suggests a clinical case of leprosy with eyebrows involvement and multiple nodular lesions except for the short duration. The child is diagnosed as a case of multibacillary child Hansen\'s and was treated with multidrug therapy, consisting of monthly doses of rifampicin 450 mg and clofazimine 200 mg, plus daily doses of dapsone 50 mg, and clofazimine 50 mg. In view of this statement, we feel strongly that the author might tried to say regarding the standard child (ages 10--14 years) treatment regimen for multibacillary leprosy as rifampicin 450 mg once a month, clofazimine 150 mg once a month and 50 mg every other day, and dapsone 50 mg daily for 12 months\[[@ref2]\] instead of what it might be wrongly typed as above.

Second, the authors have said that Guizhou Province has the second highest prevalence and new case detection rates in China with multibacillary leprosy. Along with this multibacillary in a child case indicates the active transmission of bacteria to a child from point sources that alerts the situation.

Finally, the important aspects of finding and reporting or publishing leprosy cases are, to screen early and to find, treat the cases as early as possible. Here, in this case, since, it is a child with good number of bacilli it is felt that the family members should be screened thoroughly followed by close contacts outside the house. There should be some sort of activities followed in India such as leprosy case detection campaign and Sparsh awareness.\[[@ref3]\]
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